Kubota Pharmaceutical Holdin (4596.T) traded down -1.67 % during a 24 hours period ending at 11:03 PM Central Europe on Monday 26th. One Kubota Pharmaceutical Holdin stock can currently be bought for about JPY 58 on popular exchanges. Current supply of Kubota Pharmaceutical Holdin stocks is 162.2 mn. Kubota Pharmaceutical Holdin has a current market capitalization of JPY 9.6 bn and approximately JPY 24.5 mn worth of Kubota Pharmaceutical Holdin was traded on exchanges in the last 24 hours. Since last month end, Kubota Pharmaceutical Holdin has traded -10.61 % down. Simple moving average of last 200 days is at JPY 84.85. The highest price of past 52 weeks was recorded at JPY 350 on 02/13/2026. 52 weeks low was at JPY 41 on 12/25/2025.
Here is how related stocks have performed in the past 24 hours:
Enechange (4169.T) traded down -1.49 % and now trades at JPY 267. Current market capitalisation for Enechange is JPY 11.3 bn. Enechange has a current price to earnings ratio of 33.57.
Tsubaki Nakashima (6464.T) traded down -0.67 % and now trades at JPY 290. Tsubaki Nakashima has a market capitalisation of JPY 11.3 bn.
Smartdrive (5137.T) traded up 0.33 % and now trades at JPY 303. Smartdrive has a market capitalisation of JPY 11.4 bn.
Wolves Hand (194A.T) traded down -2.57 % and now trades at JPY 1,553. Wolves Hand has a market capitalisation of JPY 11.2 bn.
Starts Publishing (7849.T) traded up 0.2 % and now trades at JPY 2,953. Starts Publishing has a market capitalisation of JPY 11.4 bn. Current price/earnings ratio for Starts Publishing is 9.76.
About Kubota Pharmaceutical Holdin
Kubota Pharmaceutical Holdings Co., Ltd. is a health care company with its operations in Tokyo, Japan. The company specializes in developing therapeutics to treat sight-threatening diseases and disorders globally. Their lead drug candidate emixustat hydrochloride is an oral administered drug for treating retinal diseases. Additionally, they are developing human rhodopsin-based gene therapy for patients suffering from retinitis pigmentosa; lanosterol-based pharmaceutical treatment for cataracts and presbyopia; and small molecule pharmacologic treatment for age-related macular degeneration, diabetic macular edema, and other retinal neovascular conditions. The company also devises home-based, patient self-monitoring optical coherence tomography devices. Kubota Pharmaceutical Holdings Co., Ltd. was established in 2002.